New mRNA vaccine for mpox enters african trials

NCT ID NCT07379580

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

Summary

This study is testing a new mpox vaccine made with mRNA technology, similar to some COVID-19 vaccines. It aims to see if the vaccine is safe and if it triggers a good immune response in healthy adults. The trial will enroll about 310 people in African countries, including those who have never been exposed to mpox or smallpox and those who have.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPOX (MONKEYPOX) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Desmond Tutu Health Foundation Masiphumelele Clinic
NOT_YET_RECRUITING

Cape Town, 7975, South Africa
Institute National de Recherche Biomedicale
NOT_YET_RECRUITING

Kinshasa, 5345, Democratic Republic of the Congo
Perinatal HIV Research Unit
RECRUITING

Johannesburg, 1864, South Africa
TASK Applied Science
NOT_YET_RECRUITING

Cape Town, 7405, South Africa
TREAD Research Pty Ltd
RECRUITING

Cape Town, 7530, South Africa
University of Kinshasa UNIKIN
NOT_YET_RECRUITING

Kinshasa, 01306, Democratic Republic of the Congo

Conditions

Explore the condition pages connected to this study.

MPOX (MONKEYPOX) ORTHOPOXVIRUS INFECTION SMALLPOX